Kritika Sarmah
2 min read
In This Article:
With a market cap of $13.1 billion, IDEX Corporation (IEX) is an Illinois-based industrial company that makes mission-critical fluidics systems, pumps, and safety equipment. It operates in niche markets like life sciences, fire & rescue, and precision engineering.
Companies valued at $10 billion or more are generally considered “large-cap” stocks, and IDEX fits this criterion perfectly. Known for its decentralized structure and strong innovation culture, IDEX serves global industries with reliable, high-margin products. It recently acquired Mott Corporation to expand in the biotech and semiconductor markets.
-
Make Over a 2.4% One-Month Yield Shorting Nvidia Out-of-the-Money Puts
-
Is Quantum Computing (QUBT) Stock a Buy on This Bold Technological Breakthrough?
Despite its notable strengths, IEX shares have retreated 27.3% from their 52-week high of $238.22 touched on Nov. 6. Shares of the company declined 5.8% over the past three months, trailing the S&P 500 Index’s ($SPX) 5.4% uptick during the same time frame.
IEX stock is down 17.3% on a YTD basis, lagging behind $SPX’s 1.5% rise. In addition, shares of IDEX have dropped 14.8% over the past 52 weeks, compared to $SPX’s 9% rally over the same time frame.
The stock has been trading below its 200-day moving average since early February and under its 50-day moving average for the past few trading sessions, indicating a downtrend.
IDEX released Q1 2025 results on May 1, and its stock rose 3.5%. Its revenue rose 2% year-over-year to $814.3 million, and adjusted EPS stood at $1.75, both topping Wall Street estimates. While organic sales slipped 1%, the company recorded an all-time high in orders at $872 million, led by solid growth in its Health & Science Technologies and Fire & Safety/Diversified Products segments. Maintaining confidence in its outlook, IDEX reaffirmed full-year guidance of $8.10–$8.45 EPS and 1–3% organic sales growth.
However, its rival, Eaton Corporation plc (ETN), has declined marginally on a YTD basis and has climbed 2.5% over the past year, outpacing IEX.
The stock has a consensus rating of “Moderate Buy” from 11 analysts covering it. Its mean price target of $208.10 represents a 20.2% potential upswing from the current market prices.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
